CRESCENT BIOPHARMA, INC. Stock Split Ratio
CRESCENT BIOPHARMA, INC. (CBIO) had Stock Split Ratio of 1.00% as of 2025-06-13, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2015 was 30.00%, a 0.00% change from fiscal 2014.
- CRESCENT BIOPHARMA, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2014 was 30.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|
| 2025-06-13 | 1.00% 10-Q · filed 2026-07-30 | ||
| 2015-12-31 | 30.00% 10-K · filed 2016-02-29 | ||
| 2014-12-31 | 30.00% 10-K · filed 2015-03-16 | ||
| 2014-09-30 | 30.00% 10-Q · filed 2014-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |